Table Of ContentFundamental Biomedical Technologies
Aleš Prokop
Volkmar Weissig E ditors
Intracellular
Delivery III
Market Entry Barriers of Nanomedicines
Fundamental Biomedical Technologies
Volume 8
Series Editor
Mauro Ferrari, Ph.D. The University of Texas, Houston, TX, USA
More information about this series at h ttp://www.springer.com/series/7045
Aleš Prokop (cid:129) Volkmar Weissig
Editors
Intracellular Delivery III
Market Entry Barriers of Nanomedicines
Editors
Aleš Prokop Volkmar Weissig
Biomolecular and Chemical Engineering Pharmaceutical Sciences
Vanderbilt University Biomolecular and Midwestern University Pharmaceutical
Chemical Engineering Sciences
Nashville , TN , USA GLENDALE , AZ , USA
Intracellular Delivery I: 978-94-007-1247-8
Intracellular Delivery II: ISBN 9 78-94-017-8895-3
ISSN 1559-7083
Fundamental Biomedical Technologies
ISBN 978-3-319-43523-7 ISBN 978-3-319-43525-1 (eBook)
DOI 10.1007/978-3-319-43525-1
Library of Congress Control Number: 2014939942
© Springer International Publishing Switzerland 2016
T his work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of
the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation,
broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information
storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology
now known or hereafter developed.
T he use of general descriptive names, registered names, trademarks, service marks, etc. in this publication
does not imply, even in the absence of a specifi c statement, that such names are exempt from the relevant
protective laws and regulations and therefore free for general use.
T he publisher, the authors and the editors are safe to assume that the advice and information in this book
are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the
editors give a warranty, express or implied, with respect to the material contained herein or for any errors
or omissions that may have been made.
Printed on acid-free paper
This Springer imprint is published by Springer Nature
The registered company is Springer International Publishing AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Contents
Part I Introductory Chapters
1 Overview of Present Problems Facing Commercialization
of Nanomedicines .................................................................................... 3
Aleš Prokop and Volkmar Weissig
2 Precision Drugs and Cell-Specific Drug Delivery ................................ 37
Karel Petrak
Part II EPR Effect and ECM Modifi cation
3 Extracellular Matrix Degrading Enzymes for Nanocarrier-Based
Anticancer Therapy ................................................................................ 49
Pablo Scodeller
4 Nanocarrier-Based Anticancer Therapies with the Focus
on Strategies for Targeting the Tumor Microenvironment ................. 67
Fransisca Leonard and Biana Godin
Part III How to Extend the Circulation Time of Nanovehicles
5 A New Approach to Decrease the RES Uptake of Nanodrugs
by Pre-administration with Intralipid® Resulting
in a Reduction of Toxic Side Effects ...................................................... 125
Li Liu and Chien Ho
Part IV Differences Between In Vivo Status in Men and Mice
6 Authentic Vascular and Stromal Structure in Animal
Disease Model for Nanomedicine........................................................... 149
Hiroshi Nishihara and Mitsunobu R. Kano
v
vi Contents
Part V Cell-Specifi c Targeting
7 Ligand-targeted Particulate Nanomedicines Undergoing
Clinical Evaluation: Current Status ...................................................... 163
Roy van der Meel , Laurens J. C. Vehmeijer , Robbert Jan Kok ,
Gert Storm , and Ethlinn V. B. van Gaal
8 Anti-angiogenic Therapy by Targeting the Tumor Vasculature
with Liposomes ........................................................................................ 201
Yu Sakurai and Hideyoshi Harashima
9 Accessing Mitochondrial Targets Using NanoCargos .......................... 229
Ru Wen , Afoma C. Umeano , and Shanta Dhar
10 Redox-Responsive Nano-Delivery Systems for Cancer Therapy ........ 255
Amit Singh , Thanh-Huyen Tran , and Mansoor M. Amiji
Part VI Improved Imaging
11 Nano-emulsions for Drug Delivery and Biomedical Imaging ............. 273
Nicolas Anton , François Hallouard , Mohamed F. Attia ,
and Thierry F. Vandamme
12 The Tumor Microenvironment in Nanoparticle Delivery
and the Role of Imaging to Navigate Roadblocks and Pathways ....... 301
Dmitri Artemov and Zaver M. Bhujwalla
13 Microscopic Mass Spectrometry for the Precise
Design of Drug Delivery Systems ........................................................... 323
Yasuhiro M atsumura and Masahiro Yasunaga
Part VII Quantitative PK Treatment, Systems
Biology and Drug Discovery
14 Pharmacokinetics and Pharmacodynamics
of Nano-Drug Delivery Systems ............................................................. 341
Amit Ranjan Maity and David Stepensky
15 PBPK Modelling of Intracellular Drug Delivery Through Active
and Passive Transport Processes ........................................................... 363
Lars Kuepfer , Christoph Niederalt , Thomas Wendl ,
Jan-Frederik Schlender , Michael Block , Thomas Eissing ,
and Donato Teutonico
16 Exploiting Nanocarriers for Combination Cancer Therapy ............... 375
Yi Wen Kong , Erik C. Dreaden , Paula T. Hammond ,
and Michael B. Yaffe
Contents vii
Part VIII Market Situation and Commercialization
of Nanotechnology
17 The Commercialization of Medical Nanotechnology
for Medical Applications......................................................................... 405
David W. Hobson
Index ................................................................................................................. 451
Contributors
Mansoor M. Amiji Department of Pharmaceutical Sciences , School of Pharmacy,
Bouve College of Health Sciences, Northeastern University , Boston , MA , USA
Nicolas Anton CNRS UMR 7199, Laboratoire de Conception et Application de
Molécules Bioactives, équipe de Pharmacie Biogalénique, U niversity of Strasbourg,
Illkirch Cedex , France
Dmitri Artemov Division of Cancer Imaging Research, Department of Radiology ,
The Johns Hopkins University School of Medicine , Baltimore , MD , USA
Mohamed F. Attia CNRS UMR 7199, Laboratoire de Conception et Application
de Molécules Bioactives, équipe de Pharmacie Biogalénique , University of
Strasbourg , Illkirch Cedex , France
National Research Center , Cairo , Egypt
Zaver M. Bhujwalla Division of Cancer Imaging Research, Department of
Radiology, T he Johns Hopkins University School of Medicine, B altimore, M D,
USA
Michael Block C omplex Systems Modelling, Bayer Technology Service GmbH,
Leverkusen , Germany
Shanta Dhar NanoTherapeutics Research Laboratory, Department of
Biochemistry and Molecular Biology, Sylvester Comprehensive Cancer Center,
Miller School of Medicine , University of Miami , Miami , FL , USA
Erik C. Dreaden Koch Institute for Integrative Cancer Research , Massachusetts
Institute of Technology , Cambridge , MA , USA
Department of Chemical Engineering , Massachusetts Institute of Technology ,
Cambridge , MA , USA
Thomas Eissing Complex Systems Modelling, Bayer Technology Service GmbH ,
Leverkusen , Germany
ix
x Contributors
Biana Godin Department of Nanomedicine , Houston Methodist Research Institute ,
Houston , T X , USA
François Hallouard DC2N Inserm U982, Laboratoire de Pharmacie Galénique
Biopharmacie, Faculté de Médicine & Pharmacie, U niversité de Rouen, R ouen,
France
Service de Pharmacie, Centre Hospitalier Asselin Hédelin , Yvetot , France
Paula T. Hammond Koch Institute for Integrative Cancer Research , Massachusetts
Institute of Technology , Cambridge , MA , USA
Department of Chemical Engineering , Massachusetts Institute of Technology ,
Cambridge , MA , USA
I nstitute for Soldier Nanotechnologies, M assachusetts Institute of Technology,
Cambridge , MA , USA
Hideyoshi Harashima Faculty of Pharmaceutical Sciences , Hokkaido University ,
Sapporo , Japan
Chien Ho Department of Biological Sciences , Carnegie Mellon University ,
Pittsburgh , PA , USA
David W. Hobson LoneStar PharmTox LLC , Bergheim , TX , USA
Mitsunobu R. Kano D epartment of Pharmaceutical Biomedicine, Graduate
School of Medicine, Dentistry, and Pharmaceutical Sciences , Okayama University ,
Okayama , Japan
Robbert Jan Kok Department of Pharmaceutics, Utrecht Institute for
Pharmaceutical Sciences (UIPS) , Utrecht University , Utrecht , The Netherlands
Yi Wen Kong Koch Institute for Integrative Cancer Research , Massachusetts
Institute of Technology , Cambridge , MA , USA
Department of Biology , Massachusetts Institute of Technology , Cambridge , MA ,
USA
Lars Kuepfer C omplex Systems Modelling, Bayer Technology Service GmbH,
Leverkusen , Germany
Fransisca Leonard Department of Nanomedicine , Houston Methodist Research
Institute , Houston , TX , USA
Li Liu Department of Biological Sciences , Carnegie Mellon University , Pittsburgh ,
PA , USA
Amit Ranjan Maity Department of Clinical Biochemistry and Pharmacology,
Faculty of Health Sciences , Ben-Gurion University of the Negev , Beer-Sheva , Israel
Yasuhiro Matsumura D ivision of Developmental Therapeutics, Exploratory
Oncology Research & Clinical Trial Center , National Cancer Center , Kashiwa ,
Japan
